This article is more than 5 years old. Information may no longer be current.
EyeGate Pharma receives grants to further develop lead product candidate, ocular drug delivery system
Click Here to Manage Email Alerts
WALTHAM, Mass. — EyeGate Pharma has received four federal grants worth nearly $1 million to further develop a dexamethasone-derived corticosteroid solution that has shown potential for treating dry eye and anterior uveitis as well as use of the company's current EyeGate II ocular drug delivery system, the company announced.
"The funds will help accelerate product development and enable us to more rapidly expand broader utilities," Stephen From, president and CEO of EyeGate Pharma, said in the release. "The continued development of our product could revolutionize how patients with ocular conditions are treated with novel therapeutics. We continue to pursue partnerships with pharmaceutical and biotechnology companies that are developing novel products for eye disease."
To date, EyeGate Pharma has conducted two randomized, double-masked phase 2 studies that evaluated EGP-437, the company's lead product candidate, when administered via the EyeGate II delivery system: one in dry eye syndrome and one in anterior uveitis. Currently, the company is recruiting patients for its phase 3 ALLUVION (Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for the treatment of dry eye in the controlled adverse environment model) study.